Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)
A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma
3 other identifiers
interventional
1,902
22 countries
389
Brief Summary
Primary Objective: To evaluate the efficacy of dupilumab (SAR231893 / REGN668) in participants with persistent asthma. Secondary Objectives:
- To evaluate the safety and tolerability of dupilumab.
- To evaluate the effect of dupilumab on improving participant-reported outcomes including health-related quality of life.
- To evaluate dupilumab systemic exposure and incidence of anti-drug antibodies.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3 asthma
Started Apr 2015
Typical duration for phase_3 asthma
389 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 8, 2015
CompletedFirst Posted
Study publicly available on registry
April 13, 2015
CompletedStudy Start
First participant enrolled
April 27, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 29, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
November 23, 2017
CompletedResults Posted
Study results publicly available
October 23, 2018
CompletedOctober 23, 2018
June 1, 2018
2.3 years
April 8, 2015
July 27, 2018
October 19, 2018
Conditions
Outcome Measures
Primary Outcomes (2)
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: Intent-to-Treat (ITT) Population
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
Baseline to Week 52
Absolute Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12: ITT Population
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Baseline, Week 12
Secondary Outcomes (37)
Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population
Baseline, Week 12
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.15 Giga/L
Baseline to Week 52
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.15 Giga/L
Baseline, Week 12
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.3 Giga/L
Baseline to Week 52
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.3 Giga/L
Baseline, Week 12
- +32 more secondary outcomes
Study Arms (4)
Placebo (for Dupilumab 200 mg) q2w
PLACEBO COMPARATOR2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection every 2 weeks (q2w) from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
Dupilumab 200 mg q2w
EXPERIMENTAL2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
Placebo (for Dupilumab 300 mg) q2w
PLACEBO COMPARATOR2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
Dupilumab 300 mg q2w
EXPERIMENTAL2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines . Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
Interventions
Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
Oral inhalation, stable dose (medium or high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy)
Oral inhalation as needed
Oral inhalation as needed
Eligibility Criteria
You may qualify if:
- Adults and adolescent participants with a physician diagnosis of asthma for ≥12 months, based on the Global Initiative for Asthma (GINA) 2014 Guidelines and the following criteria:
- a) Existing treatment with medium to high dose ICS (≥250 mcg of fluticasone propionate twice daily or equipotent ICS daily dosage to a maximum of 2000 mcg/day of fluticasone propionate or equivalent) in combination with a second controller (eg, long-acting beta agonist, leukotriene receptor antagonist) for at least 3 months with a stable dose ≥1 month prior to Visit 1.
- i) Note for Japan: for participants aged 18 years and older, ICS must be on ≥200 mcg of fluticasone propionate twice daily or equivalent; for participants aged 12 to 17 years, ICS must be ≥100 mcg of fluticasone propionate twice daily or equivalent).
- ii) Participants requiring a third controller for their asthma will be considered eligible for this study, and it should also be used for at least 3 months with a stable dose ≥1 month prior to Visit 1.
You may not qualify if:
- Participants \<12 years of age or the minimum legal age for adolescents in the country of the investigative site, whichever is higher (For those countries where local regulations permit enrollment of adults only, participant recruitment will be restricted to those who are ≥18 years of age).
- Weight is less than 30 kilograms.
- Chronic obstructive pulmonary disease or other lung diseases (eg, idiopathic pulmonary fibrosis, Churg-Strauss Syndrome, etc) which may impair lung function.
- A participant who experiences a severe asthma exacerbation (defined as a deterioration of asthma that results in emergency treatment, hospitalization due to asthma, or treatment with systemic steroids at any time from 1 month prior to the Screening Visit up to and including the Baseline Visit).
- Evidence of lung disease(s) other than asthma, either clinical evidence or imaging (Chest X-ray, CT, MRI) within 12 months of Visit 1 or at the screening visit, as per local standard of care.
- Note for Japan: According to the request from the health authority, chest X-ray should be performed at screening visit if there is no chest imaging (Chest X-ray, computed tomography \[CT\], magnetic resonance imaging \[MRI\]) available within 3 months prior to screening to exclude participants with suspected active or untreated latent tuberculosis.
- Current smoker or cessation of smoking within 6 months prior to Visit 1.
- Previous smoker with a smoking history \>10 pack-years.
- Comorbid disease that might interfere with the evaluation of Investigational Medicinal Product.
- The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sanofilead
- Regeneron Pharmaceuticalscollaborator
Study Sites (389)
Investigational Site Number 840047
Birmingham, Alabama, 35209, United States
Investigational Site Number 840056
Flagstaff, Arizona, 86001, United States
Investigational Site Number 840099
Gilbert, Arizona, 85234, United States
Investigational Site Number 840087
Scottsdale, Arizona, 85251, United States
Investigational Site Number 840132
Little Rock, Arkansas, 72209, United States
Investigational Site Number 840109
Bakersfield, California, 93301, United States
Investigational Site Number 840052
Costa Mesa, California, 92626, United States
Investigational Site Number 840116
Fresno, California, 93720, United States
Investigational Site Number 840045
Long Beach, California, 90720, United States
Investigational Site Number 840011
Los Angeles, California, 90025, United States
Investigational Site Number 840061
Los Angeles, California, 90048, United States
Investigational Site Number 840097
Los Angeles, California, 90064, United States
Investigational Site Number 840019
Mission Viejo, California, 92691, United States
Investigational Site Number 840125
Newport Beach, California, 92663, United States
Investigational Site Number 840041
North Hollywood, California, 91606, United States
Investigational Site Number 840036
Redwood City, California, 94063, United States
Investigational Site Number 840020
Rolling Hills Estates, California, 90274, United States
Investigational Site Number 840074
Roseville, California, 95661, United States
Investigational Site Number 840021
San Jose, California, 95117, United States
Investigational Site Number 840004
Centennial, Colorado, 80112, United States
Investigational Site Number 840025
Colorado Springs, Colorado, 80907, United States
Investigational Site Number 840034
Denver, Colorado, 80230, United States
Investigational Site Number 840130
Denver, Colorado, 80246, United States
Investigational Site Number 840102
New Haven, Connecticut, 06504, United States
Investigational Site Number 840037
Aventura, Florida, 33180, United States
Investigational Site Number 840018
Boynton Beach, Florida, 33472, United States
Investigational Site Number 840105
Brandon, Florida, 33511, United States
Investigational Site Number 840092
Clearwater, Florida, 33765, United States
Investigational Site Number 840122
Hialeah, Florida, 33012, United States
Investigational Site Number 840053
Loxahatchee Groves, Florida, 33470, United States
Investigational Site Number 840069
Miami, Florida, 33173, United States
Investigational Site Number 840123
Ocala, Florida, 34471, United States
Investigational Site Number 840071
Ocala, Florida, 34474, United States
Investigational Site Number 840115
Ocoee, Florida, 34761, United States
Investigational Site Number 840055
Sarasota, Florida, 34239, United States
Investigational Site Number 840114
South Miami, Florida, 33143, United States
Investigational Site Number 840048
Tampa, Florida, 33612, United States
Investigational Site Number 840084
Gainesville, Georgia, 30506, United States
Investigational Site Number 840044
Savannah, Georgia, 31406, United States
Investigational Site Number 840079
Twin Falls, Idaho, 83301, United States
Investigational Site Number 840101
Chicago, Illinois, 60611, United States
Investigational Site Number 840015
River Forest, Illinois, 60305, United States
Investigational Site Number 840089
Iowa City, Iowa, 52242, United States
Investigational Site Number 840032
Fort Mitchell, Kentucky, 41017, United States
Investigational Site Number 840009
Owensboro, Kentucky, 42303, United States
Investigational Site Number 840064
Bangor, Maine, 04401, United States
Investigational Site Number 840080
Baltimore, Maryland, 21237, United States
Investigational Site Number 840017
Chevy Chase, Maryland, 20815, United States
Investigational Site Number 840073
Gaithersburg, Maryland, 20878, United States
Investigational Site Number 840127
White Marsh, Maryland, 21162, United States
Investigational Site Number 840014
North Dartmouth, Massachusetts, 02747, United States
Investigational Site Number 840005
Minneapolis, Minnesota, 55402, United States
Investigational Site Number 840013
Kansas City, Missouri, 64111, United States
Investigational Site Number 840002
St Louis, Missouri, 63141, United States
Investigational Site Number 840093
St Louis, Missouri, 63141, United States
Investigational Site Number 840026
Missoula, Montana, 59808, United States
Investigational Site Number 840078
Omaha, Nebraska, 68131, United States
Investigational Site Number 840003
Papillion, Nebraska, 27103, United States
Investigational Site Number 840111
Brick, New Jersey, 08723, United States
Investigational Site Number 840068
Ocean City, New Jersey, 07712, United States
Investigational Site Number 840016
Princeton, New Jersey, 08540, United States
Investigational Site Number 840096
Toms River, New Jersey, 08775, United States
Investigational Site Number 840106
Jamaica, New York, 11435, United States
Investigational Site Number 840065
New York, New York, 10029, United States
Investigational Site Number 840076
Rochester, New York, 14642, United States
Investigational Site Number 840031
The Bronx, New York, 10457, United States
Investigational Site Number 840126
Charlotte, North Carolina, 28226, United States
Investigational Site Number 840083
Charlotte, North Carolina, 28277, United States
Investigational Site Number 840108
Durham, North Carolina, 27705, United States
Investigational Site Number 840107
Greensboro, North Carolina, 27403, United States
Investigational Site Number 840007
High Point, North Carolina, 27262, United States
Investigational Site Number 840046
Cincinnati, Ohio, 45241, United States
Investigational Site Number 840049
Middleburg Heights, Ohio, 44130, United States
Investigational Site Number 840042
Toledo, Ohio, 43617, United States
Investigational Site Number 840112
Edmond, Oklahoma, 73034, United States
Investigational Site Number 840121
Oklahoma City, Oklahoma, 73103, United States
Investigational Site Number 840104
Tulsa, Oklahoma, 74136, United States
Investigational Site Number 840040
Clackamas, Oregon, 97015, United States
Investigational Site Number 840039
Medford, Oregon, 97504, United States
Investigational Site Number 840001
Portland, Oregon, 97223, United States
Investigational Site Number 840085
Hershey, Pennsylvania, 17033, United States
Investigational Site Number 840081
Philadelphia, Pennsylvania, 19102, United States
Investigational Site Number 840010
Philadelphia, Pennsylvania, 19107, United States
Investigational Site Number 840067
Philadelphia, Pennsylvania, 19140, United States
Investigational Site Number 840028
Pittsburgh, Pennsylvania, 15213, United States
Investigational Site Number 840091
Pittsburgh, Pennsylvania, 15241, United States
Investigational Site Number 840029
Lincoln, Rhode Island, 02286, United States
Investigational Site Number 840082
Charleston, South Carolina, 29407, United States
Investigational Site Number 840117
Greenville, South Carolina, 29607, United States
Investigational Site Number 840100
Greer, South Carolina, 29651, United States
Investigational Site Number 840054
Spartanburg, South Carolina, 29303, United States
Investigational Site Number 840062
Amarillo, Texas, 79106, United States
Investigational Site Number 840098
Austin, Texas, 78759, United States
Investigational Site Number 840038
Boerne, Texas, 78006, United States
Investigational Site Number 840124
Cypress, Texas, 77429, United States
Investigational Site Number 840008
Dallas, Texas, 75231, United States
Investigational Site Number 840094
Dallas, Texas, 75246, United States
Investigational Site Number 840023
El Paso, Texas, 79903, United States
Investigational Site Number 840022
Fort Worth, Texas, 76109, United States
Investigational Site Number 840027
Fort Worth, Texas, 76244, United States
Investigational Site Number 840066
Killeen, Texas, 76542, United States
Investigational Site Number 840050
Live Oak, Texas, 78233, United States
Investigational Site Number 840070
McKinney, Texas, 75069, United States
Investigational Site Number 840128
McKinney, Texas, 75071, United States
Investigational Site Number 840118
Plano, Texas, 75093, United States
Investigational Site Number 840012
San Antonio, Texas, 78229, United States
Investigational Site Number 840129
San Antonio, Texas, 78251, United States
Investigational Site Number 840133
Sealy, Texas, 77474, United States
Investigational Site Number 840119
Spring, Texas, 77380, United States
Investigational Site Number 840035
Draper, Utah, 84020, United States
Investigational Site Number 840077
Murray, Utah, 84107, United States
Investigational Site Number 840057
South Burlington, Vermont, 05403, United States
Investigational Site Number 840059
Fairfax, Virginia, 22030, United States
Investigational Site Number 840113
Richmond, Virginia, 23294, United States
Investigational Site Number 840051
Bellevue, Washington, 98225, United States
Investigational Site Number 840043
Spokane, Washington, 99202, United States
Investigational Site Number 032006
Bahía Blanca, B8000JRB, Argentina
Investigational Site Number 032002
Buenos Aires, C1121ABE, Argentina
Investigational Site Number 032011
Caba, 1120, Argentina
Investigational Site Number 032007
Caba, C1414AIF, Argentina
Investigational Site Number 032001
Caba, C1425BEN, Argentina
Investigational Site Number 032003
Caba, C1425FVH, Argentina
Investigational Site Number 032010
Caba, C1426ABP, Argentina
Investigational Site Number 032005
Capital Federal, C1425DUC, Argentina
Investigational Site Number 032008
La Plata, B1900DXM, Argentina
Investigational Site Number 032004
Rosario, S2000JKR, Argentina
Investigational Site Number 032012
San Miguel de Tucumán, T4000CHE, Argentina
Investigational Site Number 032009
San Miguel de Tucumán, T4000IAR, Argentina
Investigational Site Number 036005
Campbelltown, 2560, Australia
Investigational Site Number 036001
Clayton, 3168, Australia
Investigational Site Number 036002
Frankston, 3199, Australia
Investigational Site Number 036006
Glen Osmond, 5064, Australia
Investigational Site Number 036003
Murdoch, 6150, Australia
Investigational Site Number 036004
Parkville, 3050, Australia
Investigational Site Number 076009
Florianópolis, 88040-970, Brazil
Investigational Site Number 076007
Porto Alegre, 90020-090, Brazil
Investigational Site Number 076001
Porto Alegre, 90610-000, Brazil
Investigational Site Number 076003
Salvador, 41940-455, Brazil
Investigational Site Number 076013
São Bernardo do Campo, 09715-090, Brazil
Investigational Site Number 076012
São Paulo, 04266-010, Brazil
Investigational Site Number 076008
São Paulo, 05403-000, Brazil
Investigational Site Number 076006
São Paulo, 05437-010, Brazil
Investigational Site Number 076002
Sorocaba, 18040-425, Brazil
Investigational Site Number 124019
Burlington, L7N 3V2, Canada
Investigational Site Number 124009
Calgary, T2N 4Z6, Canada
Investigational Site Number 124003
Mississauga, L5A 3V4, Canada
Investigational Site Number 124001
Montreal, H2W 1T8, Canada
Investigational Site Number 124012
Montreal, H4A 3J1, Canada
Investigational Site Number 124010
Montreal, H4J 1C5, Canada
Investigational Site Number 124013
Ottawa, K1G 6C6, Canada
Investigational Site Number 124018
Québec, G1V 4G5, Canada
Investigational Site Number 124014
Québec, G1V 4W2, Canada
Investigational Site Number 124008
Sherbrooke, J1H 5N4, Canada
Investigational Site Number 124015
Toronto, M5G 1E2, Canada
Investigational Site Number 124002
Toronto, M5T 3A9, Canada
Investigational Site Number 124007
Trois-Rivières, G8T 7A1, Canada
Investigational Site Number 124006
Vancouver, V5Z 1M9, Canada
Investigational Site Number 152015
Concepción, 41, Chile
Investigational Site Number 152003
Quillota, 2260877, Chile
Investigational Site Number 152014
Santiago, 7500588, Chile
Investigational Site Number 152001
Santiago, 7500692, Chile
Investigational Site Number 152002
Santiago, 7500698, Chile
Investigational Site Number 152008
Santiago, 7500710, Chile
Investigational Site Number 152017
Santiago, 7560994, Chile
Investigational Site Number 152007
Santiago, 8207257, Chile
Investigational Site Number 152005
Santiago, 8380456, Chile
Investigational Site Number 152009
Santiago, 8910131, Chile
Investigational Site Number 152004
Talca, 3460001, Chile
Investigational Site Number 152013
Talcahuano, 427918, Chile
Investigational Site Number 152016
Temuco, 4781156, Chile
Investigational Site Number 152010
Valdivia, Chile
Investigational Site Number 152011
Viña del Mar, 2520594, Chile
Investigational Site Number 152012
Viña del Mar, Chile
Investigational Site Number 170006
Bogotá, 110131, Colombia
Investigational Site Number 170001
Bogotá, 110221, Colombia
Investigational Site Number 170002
Bogotá, 110231, Colombia
Investigational Site Number 170003
Bogotá, 111321, Colombia
Investigational Site Number 250002
Brest, 29609, France
Investigational Site Number 250013
Lille, 59000, France
Investigational Site Number 250011
Lille, 59037, France
Investigational Site Number 250004
Lyon, 69317, France
Investigational Site Number 250010
Marseille, 13015, France
Investigational Site Number 250005
Montpellier, 34295, France
Investigational Site Number 250003
Nantes, 44093, France
Investigational Site Number 250012
Paris, 75012, France
Investigational Site Number 250001
Paris, 75018, France
Investigational Site Number 250008
Strasbourg, 67091, France
Investigational Site Number 250014
Vandœuvre-lès-Nancy, 54511, France
Investigational Site Number 276006
Berlin, 10787, Germany
Investigational Site Number 276003
Bochum, 44789, Germany
Investigational Site Number 276010
Frankfurt am Main, 60596, Germany
Investigational Site Number 276004
Hanover, 30625, Germany
Investigational Site Number 276009
Koblenz, 56068, Germany
Investigational Site Number 276007
Lübeck, 23538, Germany
Investigational Site Number 276001
Mainz, 55131, Germany
Investigational Site Number 276005
Rüdersdorf, 15562, Germany
Investigational Site Number 348003
Gödöllö, 2100, Hungary
Investigational Site Number 380004
Ancona, 60126, Italy
Investigational Site Number 380005
Catania, 95123, Italy
Investigational Site Number 380003
Ferrara, 44124, Italy
Investigational Site Number 380006
Florence, 50134, Italy
Investigational Site Number 380010
Foggia, 71122, Italy
Investigational Site Number 380002
Modena, 41124, Italy
Investigational Site Number 380009
Palermo, 90146, Italy
Investigational Site Number 380001
Pisa, 56124, Italy
Investigational Site Number 380014
Reggio Emilia, 42123, Italy
Investigational Site Number 380011
Torino, 10128, Italy
Investigational Site Number 392185
Akashi-Shi, Japan
Investigational Site Number 392128
Asahikawa-Shi, Japan
Investigational Site Number 392118
Chiyoda-Ku, Japan
Investigational Site Number 392112
Chūōku, Japan
Investigational Site Number 392157
Fukui-shi, Japan
Investigational Site Number 392137
Fukuoka, Japan
Investigational Site Number 392117
Fukuyama-Shi, Japan
Investigational Site Number 392121
Habikino-Shi, Japan
Investigational Site Number 392154
Higashiosaka-Shi, Japan
Investigational Site Number 392109
Himeji-Shi, Japan
Investigational Site Number 392108
Hiroshima, Japan
Investigational Site Number 392158
Hiroshima, Japan
Investigational Site Number 392107
Iizuka-Shi, Japan
Investigational Site Number 392101
Isesaki-Shi, Japan
Investigational Site Number 392147
Itabashi-Ku, Japan
Investigational Site Number 392150
Kagoshima, Japan
Investigational Site Number 392178
Kagoshima, Japan
Investigational Site Number 392110
Kanazawa, Japan
Investigational Site Number 392136
Kanazawa, Japan
Investigational Site Number 392142
Kasuga-Shi, Japan
Investigational Site Number 392166
Kawaguchi-Shi, Japan
Investigational Site Number 392119
Kishiwada-Shi, Japan
Investigational Site Number 392162
Kobe, Japan
Investigational Site Number 392182
Kodaira-Shi, Japan
Investigational Site Number 392174
Kokubunji-Shi, Japan
Investigational Site Number 392131
Koshi-Shi, Japan
Investigational Site Number 392183
Koshigaya-Shi, Japan
Investigational Site Number 392129
Kurashiki-Shi, Japan
Investigational Site Number 392153
Kyoto, Japan
Investigational Site Number 392176
Kyoto, Japan
Investigational Site Number 392184
Kyoto, Japan
Investigational Site Number 392133
Machida-Shi, Japan
Investigational Site Number 392135
Matsuyama, Japan
Investigational Site Number 392172
Mibu, Japan
Investigational Site Number 392114
Minatoku, Japan
Investigational Site Number 392122
Minatoku, Japan
Investigational Site Number 392144
Minatoku, Japan
Investigational Site Number 392106
Mizunami-Shi, Japan
Investigational Site Number 392164
Muroran-Shi, Japan
Investigational Site Number 392161
Nagakute-Shi, Japan
Investigational Site Number 392163
Nagoya, Japan
Investigational Site Number 392102
Naka-Gun, Japan
Investigational Site Number 392125
Nakano, Japan
Investigational Site Number 392115
Naruto-Shi, Japan
Investigational Site Number 392187
Obihiro-Shi, Japan
Investigational Site Number 392177
Ome-Shi, Japan
Investigational Site Number 392152
Osaka Sayama-Shi, Japan
Investigational Site Number 392155
Osaka Sayama-Shi, Japan
Investigational Site Number 392170
Osaki-Shi, Japan
Investigational Site Number 392138
Ota-Shi, Japan
Investigational Site Number 392123
Oura-Gun, Japan
Investigational Site Number 392120
Ōta-ku, Japan
Investigational Site Number 392127
Ōta-ku, Japan
Investigational Site Number 392169
Sagamihara-Shi, Japan
Investigational Site Number 392149
Sapporo, Japan
Investigational Site Number 392179
Seto-Shi, Japan
Investigational Site Number 392186
Shibuya-Ku, Japan
Investigational Site Number 392139
Shinagawa-Ku, Japan
Investigational Site Number 392167
Shinagawa-Ku, Japan
Investigational Site Number 392130
Shinjuku-Ku, Japan
Investigational Site Number 392165
Sumida-Ku, Japan
Investigational Site Number 392146
Tachikawa-Shi, Japan
Investigational Site Number 392173
Tachikawa-Shi, Japan
Investigational Site Number 392103
Tokyo, Japan
Investigational Site Number 392113
Tomakomai-Shi, Japan
Investigational Site Number 392151
Tsu, Japan
Investigational Site Number 392168
Uozu-Shi, Japan
Investigational Site Number 392132
Urasoe-Shi, Japan
Investigational Site Number 392134
Uruma, Japan
Investigational Site Number 392116
Wakayama, Japan
Investigational Site Number 392140
Yokohama, Japan
Investigational Site Number 392159
Yonago-Shi, Japan
Investigational Site Number 484013
Chihuahua City, 31020, Mexico
Investigational Site Number 484006
Chihuahua City, 31200, Mexico
Investigational Site Number 484014
Cuautitlán Izcalli, 54769, Mexico
Investigational Site Number 484008
Durango, 34080, Mexico
Investigational Site Number 484001
Guadalajara, 44100, Mexico
Investigational Site Number 484004
Mexico City, 64718, Mexico
Investigational Site Number 484010
México, 06700, Mexico
Investigational Site Number 484003
Monterrey, 64460, Mexico
Investigational Site Number 484007
Monterrey, 66465, Mexico
Investigational Site Number 484012
San Juan del Río, 76800, Mexico
Investigational Site Number 484011
Veracruz, 91910, Mexico
Investigational Site Number 484015
Zapopan, 45100, Mexico
Investigational Site Number 616006
Bialystok, 15-010, Poland
Investigational Site Number 616003
Gdansk, 80-952, Poland
Investigational Site Number 616007
Krakow, 31-159, Poland
Investigational Site Number 616001
Lodz, 90-141, Poland
Investigational Site Number 616005
Lodz, 90-153, Poland
Investigational Site Number 616009
Lodz, 90-329, Poland
Investigational Site Number 616002
Poznan, 60-693, Poland
Investigational Site Number 616004
Sopot, 81-741, Poland
Investigational Site Number 616008
Strzelce Opolskie, 47-100, Poland
Investigational Site Number 643006
Moscow, 105077, Russia
Investigational Site Number 643003
Moscow, 109240, Russia
Investigational Site Number 643005
Moscow, 115280, Russia
Investigational Site Number 643002
Moscow, 117574, Russia
Investigational Site Number 643004
Moscow, 123182, Russia
Investigational Site Number 643001
Moscow, 125315, Russia
Investigational Site Number 643011
Ryazan, 390039, Russia
Investigational Site Number 643007
Saint Petersburg, 193231, Russia
Investigational Site Number 643008
Saint Petersburg, 194354, Russia
Investigational Site Number 643009
Saint Petersburg, 195030, Russia
Investigational Site Number 643010
Saint Petersburg, 197022, Russia
Investigational Site Number 643012
Yaroslavl, 150003, Russia
Investigational Site Number 643013
Yekaterinburg, 620109, Russia
Investigational Site Number 710011
Cape Town, 7505, South Africa
Investigational Site Number 710004
Cape Town, 7530, South Africa
Investigational Site Number 710001
Cape Town, 7700, South Africa
Investigational Site Number 710002
Cape Town, 7700, South Africa
Investigational Site Number 710010
Cape Town, 7764, South Africa
Investigational Site Number 710003
Cape Town, 8000, South Africa
Investigational Site Number 710005
Durban, 4001, South Africa
Investigational Site Number 710006
Durban, 4071, South Africa
Investigational Site Number 710007
Pretoria, 0087, South Africa
Investigational Site Number 710009
Winnie Mandela, 9400, South Africa
Investigational Site Number 410002
Bucheon-si, 14584, South Korea
Investigational Site Number 410015
Busan, 49201, South Korea
Investigational Site Number 410003
Cheongju-si, 28644, South Korea
Investigational Site Number 410013
Incheon, 21565, South Korea
Investigational Site Number 410008
Seoul, 02559, South Korea
Investigational Site Number 410006
Seoul, 03080, South Korea
Investigational Site Number 410004
Seoul, 03722, South Korea
Investigational Site Number 410012
Seoul, 04763, South Korea
Investigational Site Number 410005
Seoul, 05505, South Korea
Investigational Site Number 410007
Seoul, 06351, South Korea
Investigational Site Number 410009
Seoul, 06591, South Korea
Investigational Site Number 410010
Seoul, 06973, South Korea
Investigational Site Number 410011
Seoul, 08308, South Korea
Investigational Site Number 410001
Suwon, 16499, South Korea
Investigational Site Number 410014
Uijeongbu-si, 11765, South Korea
Investigational Site Number 724002
Barcelona, 08035, Spain
Investigational Site Number 724001
Barcelona, 08036, Spain
Investigational Site Number 724010
Palma de Mallorca, 07120, Spain
Investigational Site Number 724005
Pozuelo de Alarcón, 28223, Spain
Investigational Site Number 724004
Sant Boi de Llobregat, 08830, Spain
Investigational Site Number 724006
Santiago de Compostela, 15706, Spain
Investigational Site Number 724008
Seville, 41071, Spain
Investigational Site Number 724007
Valencia, 46017, Spain
Investigational Site Number 158004
Kaohsiung City, 807, Taiwan
Investigational Site Number 158002
Kaohsiung City, 82445, Taiwan
Investigational Site Number 158008
New Taipei City, 23561, Taiwan
Investigational Site Number 158005
Taichung, 40201, Taiwan
Investigational Site Number 158007
Taichung, 40447, Taiwan
Investigational Site Number 158001
Taipei, 10043, Taiwan
Investigational Site Number 158009
Taipei, 11031, Taiwan
Investigational Site Number 158006
Taoyuan District, 333, Taiwan
Investigational Site Number 792004
Ankara, 06100, Turkey (Türkiye)
Investigational Site Number 792008
Ankara, 06100, Turkey (Türkiye)
Investigational Site Number 792003
Bursa, 16059, Turkey (Türkiye)
Investigational Site Number 792001
Istanbul, 34098, Turkey (Türkiye)
Investigational Site Number 792007
Istanbul, 34668, Turkey (Türkiye)
Investigational Site Number 792005
Izmir, 35040, Turkey (Türkiye)
Investigational Site Number 792010
Izmir, 35110, Turkey (Türkiye)
Investigational Site Number 792011
Kocaeli, 41100, Turkey (Türkiye)
Investigational Site Number 792009
Kırıkkale, 71450, Turkey (Türkiye)
Investigational Site Number 792002
Mersin, 33070, Turkey (Türkiye)
Investigational Site Number 792006
Rize, 53100, Turkey (Türkiye)
Investigational Site Number 804007
Chernivtsi, 58001, Ukraine
Investigational Site Number 804023
Dnipro, 49101, Ukraine
Investigational Site Number 804004
Ivano-Frankivsk, 76018, Ukraine
Investigational Site Number 804009
Ivano-Frankivsk, 76018, Ukraine
Investigational Site Number 804005
Kharkiv, 61058, Ukraine
Investigational Site Number 804021
Kharkiv, 61093, Ukraine
Investigational Site Number 804001
Kharkiv, 61124, Ukraine
Investigational Site Number 804003
Kyiv, 03680, Ukraine
Investigational Site Number 804008
Kyiv, 03680, Ukraine
Investigational Site Number 804011
Kyiv, 03680, Ukraine
Investigational Site Number 804013
Kyiv, 03680, Ukraine
Investigational Site Number 804017
Kyiv, 03680, Ukraine
Investigational Site Number 804016
Kyiv, 04050, Ukraine
Investigational Site Number 804006
Odesa, 65025, Ukraine
Investigational Site Number 804002
Poltava, 36038, Ukraine
Investigational Site Number 804014
Ternopil, 46000, Ukraine
Investigational Site Number 804012
Vinnytsia, 21001, Ukraine
Investigational Site Number 804022
Zaporizhia, 69076, Ukraine
Investigational Site Number 826001
Bradford, BD9 6RJ, United Kingdom
Investigational Site Number 826002
London, EC1M 6BQ, United Kingdom
Investigational Site Number 826005
Newcastle upon Tyne, NE7 7DN, United Kingdom
Investigational Site Number 826007
Portsmouth, PO6 3LY, United Kingdom
Investigational Site Number 826006
South Shields, NE34 0PL, United Kingdom
Investigational Site Number 826003
Sutton in Ashfield, NG17 4JL, United Kingdom
Related Publications (32)
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21.
PMID: 29782217RESULTPavord ID, Wechsler ME, Busse WW, Domingo C, Xia C, Gall R, Pandit-Abid N, Jacob-Nara JA, Radwan A, Rowe PJ, Deniz Y. Dupilumab efficacy in patients with type 2 asthma and early Feno level reductions. J Allergy Clin Immunol Glob. 2025 Apr 15;4(3):100474. doi: 10.1016/j.jacig.2025.100474. eCollection 2025 Aug.
PMID: 40458676DERIVEDPavord ID, Casale TB, Corren J, FitzGerald MJ, Deniz Y, Altincatal A, Gall R, Pandit-Abid N, Radwan A, Jacob-Nara JA, Rowe PJ, Busse WW. Dupilumab Reduces Exacerbations Independent of Changes in Biomarkers in Moderate-to-Severe Asthma. J Allergy Clin Immunol Pract. 2024 Jul;12(7):1763-1772. doi: 10.1016/j.jaip.2024.03.031. Epub 2024 Mar 29.
PMID: 38555079DERIVEDPeters AT, Sagara H, Corren J, Domingo C, Altincatal A, Soler X, Pandit-Abid N, Crikelair N, Rowe PJ, Jacob-Nara JA, Deniz Y. Impact of dupilumab across seasons in patients with type 2, uncontrolled, moderate-to-severe asthma. Ann Allergy Asthma Immunol. 2024 Apr;132(4):477-484.e4. doi: 10.1016/j.anai.2023.11.021. Epub 2023 Nov 25.
PMID: 38013139DERIVEDBleecker ER, Panettieri RA Jr, Lugogo NL, Corren J, Daizadeh N, Jacob-Nara JA, Deniz Y, Rowe PJ, Khodzhayev A, Soler X, Ferro TJ, Hansen CN. Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils. J Immunol Res. 2023 Oct 19;2023:9943584. doi: 10.1155/2023/9943584. eCollection 2023.
PMID: 37901346DERIVEDCorren J, Hanania NA, Busse WW, Sher LD, Altincatal A, Hardin M, Mannent LP, Amin N, Lederer DJ, Soler X, Jacob-Nara JA, Rowe PJ, Deniz Y. Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitization. Clin Exp Allergy. 2023 Oct;53(10):1020-1030. doi: 10.1111/cea.14389. Epub 2023 Sep 26.
PMID: 37752621DERIVEDMaspero JF, Shafazand S, Cole J, Pavord ID, Busse WW, Msihid J, Gall R, Soler X, Radwan A, Khan AH, de Prado Gomez L, Jacob-Nara JA. Dupilumab efficacy in high sleep disturbance management among patients with type 2 asthma. Respir Med. 2023 Nov;218:107344. doi: 10.1016/j.rmed.2023.107344. Epub 2023 Sep 1.
PMID: 37659435DERIVEDPavord ID, Bourdin A, Papi A, Domingo C, Corren J, Altincatal A, Radwan A, Pandit-Abid N, Jacob-Nara JA, Deniz Y, Rowe PJ, Laws E, Lederer DJ, Hardin M. Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids dose. Allergy. 2023 Nov;78(11):2921-2932. doi: 10.1111/all.15792. Epub 2023 Jul 11.
PMID: 37431558DERIVEDRabe KF, Pavord ID, Busse WW, Chupp GL, Izuhara K, Altincatal A, Gall R, Pandit-Abid N, Deniz Y, Rowe PJ, Jacob-Nara JA, Radwan A. Dupilumab improves long-term outcomes in patients with uncontrolled, moderate-to-severe GINA-based type 2 asthma, irrespective of allergic status. Allergy. 2023 Aug;78(8):2148-2156. doi: 10.1111/all.15747. Epub 2023 May 21.
PMID: 37073882DERIVEDPavord ID, Deniz Y, Corren J, Casale TB, FitzGerald JM, Izuhara K, Daizadeh N, Ortiz B, Johnson RR, Harel S, Djandji M, Goga L, Crikelair N, Rowe PJ, Busse WW. Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma. J Allergy Clin Immunol Pract. 2023 Apr;11(4):1213-1220.e2. doi: 10.1016/j.jaip.2022.11.043. Epub 2022 Dec 16.
PMID: 36535524DERIVEDBerger P, Menzies-Gow A, Peters AT, Kuna P, Rabe KF, Altincatal A, Soler X, Pandit-Abid N, Siddiqui S, Jacob-Nara JA, Deniz Y, Rowe PJ. Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polyps. Ann Allergy Asthma Immunol. 2023 Feb;130(2):215-224. doi: 10.1016/j.anai.2022.11.006. Epub 2022 Nov 7.
PMID: 36356712DERIVEDBourdin A, Virchow JC, Papi A, Lugogo NL, Bardin P, Antila M, Halpin DMG, Daizadeh N, Djandji M, Ortiz B, Jacob-Nara JA, Gall R, Deniz Y, Rowe PJ. Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline. Respir Med. 2022 Oct;202:106938. doi: 10.1016/j.rmed.2022.106938. Epub 2022 Aug 11.
PMID: 36087550DERIVEDRabe KF, FitzGerald JM, Bateman ED, Castro M, Pavord ID, Maspero JF, Busse WW, Izuhara K, Daizadeh N, Ortiz B, Pandit-Abid N, Rowe PJ, Deniz Y. Dupilumab Is Effective in Patients With Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma Phenotype. J Allergy Clin Immunol Pract. 2022 Nov;10(11):2916-2924.e4. doi: 10.1016/j.jaip.2022.06.036. Epub 2022 Aug 23.
PMID: 36028446DERIVEDPapi A, Corren J, Castro M, Domingo C, Rogers L, Chapman KR, Jackson DJ, Daizadeh N, Pandit-Abid N, Gall R, Jacob-Nara JA, Rowe PJ, Deniz Y, Ortiz B. Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthma. Allergy. 2023 Jan;78(1):233-243. doi: 10.1111/all.15456. Epub 2022 Aug 9.
PMID: 35899469DERIVEDWechsler ME, Klion AD, Paggiaro P, Nair P, Staumont-Salle D, Radwan A, Johnson RR, Kapoor U, Khokhar FA, Daizadeh N, Chen Z, Laws E, Ortiz B, Jacob-Nara JA, Mannent LP, Rowe PJ, Deniz Y. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis. J Allergy Clin Immunol Pract. 2022 Oct;10(10):2695-2709. doi: 10.1016/j.jaip.2022.05.019. Epub 2022 May 28.
PMID: 35636689DERIVEDRabe KF, Pavord ID, Castro M, Wechsler ME, Daizadeh N, Kapoor U, Ortiz B, Radwan A, Johnson RR, Rowe PJ, Deniz Y, Jacob-Nara JA. Dupilumab efficacy and safety in patients with asthma and blood eosinophils >/=500 cells.microL-1. Eur Respir J. 2022 Jun 23;59(6):2102577. doi: 10.1183/13993003.02577-2021. Print 2022 Jun.
PMID: 35487538DERIVEDRhee CK, Park JW, Park HW, Cho YS. Effect of Dupilumab in Korean Patients With Uncontrolled Moderate-to-Severe Asthma: A LIBERTY ASTHMA QUEST Sub-analysis. Allergy Asthma Immunol Res. 2022 Mar;14(2):182-195. doi: 10.4168/aair.2022.14.2.182.
PMID: 35255536DERIVEDGeng B, Bachert C, Busse WW, Gevaert P, Lee SE, Niederman MS, Chen Z, Lu X, Khokhar FA, Kapoor U, Pandit-Abid N, Jacob-Nara JA, Rowe PJ, Deniz Y, Ortiz B. Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies. J Allergy Clin Immunol Pract. 2022 Mar;10(3):732-741. doi: 10.1016/j.jaip.2021.12.006. Epub 2021 Dec 22.
PMID: 34954123DERIVEDTohda Y, Matsumoto H, Miyata M, Taguchi Y, Ueyama M, Joulain F, Arakawa I. Cost-effectiveness analysis of dupilumab among patients with oral corticosteroid-dependent uncontrolled severe asthma in Japan. J Asthma. 2022 Nov;59(11):2162-2173. doi: 10.1080/02770903.2021.1996596. Epub 2021 Dec 8.
PMID: 34752208DERIVEDBusse WW, Paggiaro P, Munoz X, Casale TB, Castro M, Canonica GW, Douglass JA, Tohda Y, Daizadeh N, Ortiz B, Pandit-Abid N. Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma. Eur Respir J. 2021 Oct 7;58(4):2004605. doi: 10.1183/13993003.04605-2020. Print 2021 Oct.
PMID: 34326187DERIVEDCorren J, Katelaris CH, Castro M, Maspero JF, Ford LB, Halpin DMG, Rice MS, Radwan A, Deniz Y, Rowe PJ, Teper A, Djandji M. Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma. Eur Respir J. 2021 Oct 28;58(4):2004498. doi: 10.1183/13993003.04498-2020. Print 2021 Oct.
PMID: 34266940DERIVEDBusse WW, Wenzel SE, Casale TB, FitzGerald JM, Rice MS, Daizadeh N, Deniz Y, Patel N, Harel S, Rowe PJ, Graham NMH, O'Riordan T, Pavord ID. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Lancet Respir Med. 2021 Oct;9(10):1165-1173. doi: 10.1016/S2213-2600(21)00124-7. Epub 2021 Jun 25.
PMID: 34181876DERIVEDHamilton JD, Harel S, Swanson BN, Brian W, Chen Z, Rice MS, Amin N, Ardeleanu M, Radin A, Shumel B, Ruddy M, Patel N, Pirozzi G, Mannent L, Graham NMH. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy. 2021 Jul;51(7):915-931. doi: 10.1111/cea.13954. Epub 2021 Jun 26.
PMID: 34037993DERIVEDMaspero JF, FitzGerald JM, Pavord ID, Rice MS, Maroni J, Rowe PJ, Pirozzi G, Amin N, Ruddy M, Graham NMH, Teper A, Hardin M. Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST. Allergy. 2021 Aug;76(8):2621-2624. doi: 10.1111/all.14872. Epub 2021 May 10. No abstract available.
PMID: 33905544DERIVEDBansal A, Simpson EL, Paller AS, Siegfried EC, Blauvelt A, de Bruin-Weller M, Corren J, Sher L, Guttman-Yassky E, Chen Z, Daizadeh N, Kamal MA, Shumel B, Mina-Osorio P, Mannent L, Patel N, Graham NMH, Khokhar FA, Ardeleanu M. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma. Am J Clin Dermatol. 2021 Jan;22(1):101-115. doi: 10.1007/s40257-020-00577-1.
PMID: 33481203DERIVEDBourdin A, Papi AA, Corren J, Virchow JC, Rice MS, Deniz Y, Djandji M, Rowe P, Pavord ID. Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline. Allergy. 2021 Jan;76(1):269-280. doi: 10.1111/all.14611. Epub 2020 Oct 21.
PMID: 33010038DERIVEDTohda Y, Nakamura Y, Fujisawa T, Ebisawa M, Arima K, Miyata M, Takahashi Y, Rice MS, Deniz Y, Rowe P, Patel N, Graham NMH, Teper A. Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study. Allergol Int. 2020 Oct;69(4):578-587. doi: 10.1016/j.alit.2020.04.002. Epub 2020 May 20.
PMID: 32444306DERIVEDCorren J, Castro M, O'Riordan T, Hanania NA, Pavord ID, Quirce S, Chipps BE, Wenzel SE, Thangavelu K, Rice MS, Harel S, Jagerschmidt A, Khan AH, Kamat S, Maroni J, Rowe P, Lu Y, Amin N, Pirozzi G, Ruddy M, Graham NMH, Teper A. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. J Allergy Clin Immunol Pract. 2020 Feb;8(2):516-526. doi: 10.1016/j.jaip.2019.08.050. Epub 2019 Sep 12.
PMID: 31521831DERIVEDMaspero JF, Katelaris CH, Busse WW, Castro M, Corren J, Chipps BE, Peters AT, Pavord ID, Ford LB, Sher L, Rabe KF, Rice MS, Rowe P, Lu Y, Harel S, Jagerschmidt A, Khan AH, Kamat S, Pirozzi G, Amin N, Ruddy M, Graham NMH, Mannent LP, Teper A. Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis. J Allergy Clin Immunol Pract. 2020 Feb;8(2):527-539.e9. doi: 10.1016/j.jaip.2019.07.016. Epub 2019 Jul 24.
PMID: 31351189DERIVEDCorren J, Castro M, Chanez P, Fabbri L, Joish VN, Amin N, Graham NMH, Mastey V, Abbe A, Taniou C, Mahajan P, Teper A, Pirozzi G, Eckert L. Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. Ann Allergy Asthma Immunol. 2019 Jan;122(1):41-49.e2. doi: 10.1016/j.anai.2018.08.005. Epub 2018 Aug 21.
PMID: 30138668DERIVEDBusse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, Pavord ID, Zhang B, Staudinger H, Pirozzi G, Amin N, Akinlade B, Eckert L, Chao J, Graham NMH, Teper A. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. Adv Ther. 2018 May;35(5):737-748. doi: 10.1007/s12325-018-0702-4. Epub 2018 May 3.
PMID: 29725983DERIVEDWeinstein SF, Katial R, Jayawardena S, Pirozzi G, Staudinger H, Eckert L, Joish VN, Amin N, Maroni J, Rowe P, Graham NMH, Teper A. Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma. J Allergy Clin Immunol. 2018 Jul;142(1):171-177.e1. doi: 10.1016/j.jaci.2017.11.051. Epub 2018 Jan 31.
PMID: 29355679DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Trial Transparency Team
- Organization
- Sanofi
Study Officials
- STUDY DIRECTOR
Clinical Sciences & Operations
Sanofi
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 8, 2015
First Posted
April 13, 2015
Study Start
April 27, 2015
Primary Completion
July 29, 2017
Study Completion
November 23, 2017
Last Updated
October 23, 2018
Results First Posted
October 23, 2018
Record last verified: 2018-06